ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT Pharmaservices – Business Wire (press release)
Business Wire (press release) |
ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT Pharmaservices
Business Wire (press release) ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology. NMI Natural and Medical Sciences Institute at the University of Tübingen and its … |
